Numerous studies have shown that the degree of inflammatory response and immune dysregulation are key determinants of clinical outcomes in sepsis.[3] Accordingly, a variety of hematologic inflammation-related markers – such as C-reactive protein (CRP), procalcitonin (PCT) and tumor necrosis factor-alpha (TNF-α) – are widely used in clinical prognosis assessment.[4,5] However, these conventional biomarkers often suffer from limitations such as low specificity, high cost, or unstable dynamic changes. The gene discussed is TNF; the disease is Sepsis.